Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.…
Curis (CRIS) Stock Fair Value Falls After Q3 And Private Placement Rework
Curis (NASDAQ: CRIS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 20 employees.
The shares were at 0.4270 USD on 20 November 2026, down 98.4% over 52 weeks. Its 52-week range is 0.3250 USD to 28.40 USD: the price is 98.5% below the high and 31.4% above the low.
Its market capitalisation is 4.06M USD.
Curis reports return on equity of -138.8%.
It holds more cash than debt, a net cash position of 4.03M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 March 2027.